AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 252 min read$BBNX

Hopman Mark sold $19K of BBNX

Hopman Mark (Chief Commercial Officer) sold 1,258 shares of Beta Bionics, Inc. (BBNX) at $15.01 on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hopman Mark
Published Jun 25, 2026, 8:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Neutral
high confidence
Mentioned
$BBNX
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The disclosed transaction is an open-market sale by the Chief Commercial Officer under a pre-arranged 10b5-1 plan; the text does not include any new business, clinical, or financial developments.

02

Market read

Traders may treat this as routine insider liquidity rather than a fresh fundamental catalyst.

03

What to watch

The article provides only one sale; without context on prior/next planned tranches or total insider activity, the signal strength is weak.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-25 after-hours; reflects sale executed 2026-06-24.

Background

The article is an SEC Form 4 insider transaction disclosure for Beta Bionics, Inc.

Company-level read

Ticker impact

$BBNXNeutralHigh confidence
Context

SEC Form 4 shows CCO Hopman Mark sold 1,258 shares at $15.0083 on 2026-06-24 under a 10b5-1 plan.

Expected impact

Minimal near-term impact; any reaction is likely noise unless paired with other disclosures.

Evidence & confidence

The filing is a scheduled open-market sale (Code S) under a pre-arranged 10b5-1 plan, with no accompanying new operational or financial catalyst in the text.

Market effects

Sector

No sector-level implications disclosed; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of near-term risk, so traders may watch for clustering with other insider sales.

Key entities

  • issuer
    Beta Bionics, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Hopman Mark

    Chief Commercial Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min